

**Clinical Policy: Cysteamine Ophthalmic (Cystaran, Cystadrops)**

Reference Number: CP.PMN.130

Effective Date: 08.01.17

Last Review Date: 05.22

Line of Business: Commercial\*, HIM\*, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

**Description**

Cysteamine (Cystaran<sup>®</sup>, Cystadrops<sup>®</sup>) ophthalmic solution is a cystine-depleting agent.

*\*For Health Insurance Marketplace (HIM) and Commercial, if request is through pharmacy benefit, Cystadrops is non-formulary and should not be approved using these criteria; refer to the formulary exception policies, HIM.PA.103 for HIM and CP.CPA.190 for Commercial.*

**FDA Approved Indication(s)**

Cystaran and Cystadrops are indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.

**Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Cystaran and Cystadrops are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria****A. Corneal Cystine Crystal Accumulation (must meet all):**

1. Diagnosis of cystinosis;
2. Prescribed by or in consultation with an ophthalmologist;
3. Presence of corneal cystine accumulation;
4. Dose does not exceed one of the following (a or b):
  - a. Cystaran: 1 drop in each eye every hour while awake (1 bottle per week);
  - b. Cystadrops: 1 drop in each eye 4 times a day while awake (1 bottle per week).

**Approval duration:**

**Commercial/HIM** – 6 months for Cystaran (*for Cystadrops, refer to HIM.PA.103 for HIM and CP.CPA.190 for Commercial*)

**Medicaid** – 6 months

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Corneal Cystine Crystal Accumulation (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
  - a. Cystaran: 1 drop in each eye every hour while awake (1 bottle per week);
  - b. Cystadrops: 1 drop in each eye 4 times a day while awake (1 bottle per week).

**Approval duration:**

**Commercial/HIM** – 12 months for Cystaran (*for requests for Cystadrops, refer to HIM.PA.103 for HIM and CP.CPA.190 for Commercial*)

**Medicaid** – 12 months

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 12 months (whichever is less);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

*Appendix B: Therapeutic Alternatives*

Not applicable

*Appendix C: Contraindications/Boxed Warnings*

None reported

**V. Dosage and Administration**

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
Cystaran (cysteamine)	1 drop in each eye every waking hour	1 drop/eye/hour during waking hours
Cystadrops (cysteamine)	1 drop in each eye, 4 times a day during waking hours	See dosing regimen

**VI. Product Availability**

Drug Name	Availability
Cystaran (cysteamine)	Ophthalmic solution: 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%)
Cystadrops (cysteamine)	Ophthalmic solution containing 3.8 mg/mL of cysteamine (0.37%) in 5 mL bottle

**VII. References**

1. Cystaran Prescribing Information. Gaithersburg, MD: Leadiant Biosciences, Inc., April 2020. Available at: <http://www.cystaran.com/>. Accessed January 13, 2022.
2. Cystadrops Prescribing Information. Lebanon, NJ: Recordati Rare Diseases Inc.; August 2020. Available at: <https://www.cystadrops.com>. Accessed January 13, 2022.
3. Cystinosis. National Organization for Rare Disorders website. <https://rarediseases.org/rare-diseases/cystinosis/>. Published 1986. Updated 2020. Accessed January 13, 2022.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2018 annual review: no significant changes; Medicaid added; reference number changed from HIM.PA to CP.PMN; references reviewed and updated.	03.06.18	05.18
Added Commercial line of business as PA is required for a commercial business	06.14.18	
2Q 2019 annual review: no significant changes; references reviewed and updated	02.06.19	05.19
2Q 2020 annual review: no significant changes; references reviewed and updated	02.07.20	05.20
RT4: added Cystadrops to policy.	10.22.20	
2Q 2021 annual review: revised Cystadrops dosing in approval criteria from a maximum of 3 bottles/month to a maximum of 1 bottle/week to align with the prescribing information; references for HIM line of business off-label use revised from HIM.PHAR.21 to HIM.PA.154; references reviewed and updated.	01.29.21	05.21
2Q 2022 annual review: no significant changes; added legacy WellCare and shortened initial approval duration from 12 months to 6 months (WCG.CP.PMN.130 to be retired); added note referring reviewers to the HIM/Commercial formulary exception policies for Cystadrops requests given its NF status; references reviewed and updated.	01.13.22	05.22

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional

organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.